Instrument Inactif

Autres langues Oncomed Pharmaceuticals Inc

Actions

US68234X1028

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Celgene Corporation Announces Update on Etigilimab Partnership	14/06/19
OncoMed Pharmaceuticals, Inc. Announces Executive Resignations in Connection with the Merger Agreement	23/04/19
OncoMed Pharmaceuticals, Inc.(NasdaqGM:OMED) dropped from NASDAQ Composite Index	23/04/19
Mereo BioPharma Group plc completed the acquisition of OncoMed Pharmaceuticals, Inc. from Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC and Biotechnology Value Trading Fund OS LP managed by BVF Partners LP and others.	23/04/19
OncoMed Pharmaceuticals, Inc.(NasdaqGS:OMED) dropped from S&P TMI Index	18/04/19
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights	15/03/19
OncoMed Pharmaceuticals, Inc. Declares Special Dividend of Contingent Value Rights, Payable on April 5, 2019	15/03/19
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results	07/03/19
OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2018	07/03/19
Oncomed Pharmaceuticals, Inc. Announces Executive Changes	06/12/18
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals	05/12/18
Mereo BioPharma Group plc agreed to acquire OncoMed Pharmaceuticals, Inc. for $57.4 million.	05/12/18
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody	09/11/18
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody	09/11/18
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018	01/11/18
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer	22/10/18
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer	20/10/18
Celgene Notifies OncoMed Pharmaceuticals, Inc. of Its Decision Not to Exercise Option to License Rosmantuzumab and Subsequently Terminated the Companies’ Collaboration Agreement with Respect to Rosmantuzumab, Effective February 12, 2019	17/10/18
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting	09/10/18
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting	09/10/18

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncomed Pharmaceuticals Inc

Actions

US68234X1028

Autres langues

Filtres